AHA GUIDELINES Bundle (free trial)

Dyslipidemia 2026

AHA GUIDELINES Apps brought to you courtesy of Guideline Central. All of these titles are available for purchase on our website, GuidelineCentral.com. Enjoy!

Issue link: https://eguideline.guidelinecentral.com/i/1543908

Contents of this Issue

Navigation

Page 79 of 105

80 Management Figure 14. Managing Adults With Hypertriglyceridemia ASCVD and Hypertriglyceridemia (Fasting TG >150 to 499 mg/dL or nonfasting TG >175 to 499 mg/dL and TG <500 mg/dL)* Diabetes, Aged >40 y, Without ASCVD and Hypertriglyceridemia (Fasting TG ≥150 mg/dL to 499 mg/dL or nonfasting TG ≥175 mg/dL to 499 mg/dL)* Factors to Consider • Evaluate and manage secondary cause of hypertriglyceridemia • Optimize diet and lifestyle interventions for hypertriglyceridemia • Implement guideline-directed statin therapy in appropriate patients and optimize statin adherence • Optimize glycemic control • Monitor response to therapy and adherence • Conduct clinician-patient discussion of potential benefits, potential harms, and preference Optional Interventions to Consider • Referral to a registered dietitian nutritionist • Addition of TG risk-based medication • Screening for familial chylomicronemia syndrome • Referral to lipid specialist Persistent fasting hypertriglyceridemia * Conversion of TG from mg/dL to mmol/L: 150 mg/dL=1.7 mmol/L, 175 mg/dL=2 mmol/L, 500 mg/dL to 5.7 mmol/L, 1000 mg/dL=11.3 mmol/L. ASCVD indicates atherosclerotic cardiovascular disease; and TG, triglycerides. Adapted with permission from Virani et al. Copyright © 2021 American College of Cardiology Foundation.

Articles in this issue

Archives of this issue

view archives of AHA GUIDELINES Bundle (free trial) - Dyslipidemia 2026